Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer

• Status: Terminated
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Rationale: Computer systems that allow doctors to create a 3 dimensional (3-D) picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as cisplatin, may make tumor cells more sensitive to radiation therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abramson Cancer Center of the University of Pennsylvania
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• Subjects must have histologically confirmed squamous cell, adenosquamous or adenocarcinoma of the cervix

• Subjects must have non-metastatic FIGO Stage Ia-IVa cervical cancer

• Claustrophobic subjects must agree to be sedated during MRI procedures

• ECOG performance status of 0-2

Exclusion Criteria:

• Subjects with an inability to tolerate MR imaging

• Subjects who have had prior surgery for treatment of disease other than exploratory laparotomy or biopsy

• Study subjects who have contraindication to MRI scanning such as but not limited to subjects with pacemakers, metal fragments in the eye or certain metallic implants

• Women of childbearing potential who have a positive result on screening serum pregnancy test